Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/21/2006 5:37:01 AM
	Read Replies (1) of 933

Kosan's market cap increased by about 18 mUSD yesterday after the company announced that the KOS-2187 motilin agonsit program has been licensed to Pfizer. I am somewhat surprised by the "strong" reaction from the market's side. Maybe there was an element of pleasant surprise, that Kosan managed to license a more or less unknown program to a company like Pfizer. Pfizer, as a company on the look-out for billion-dollar drugs, was also somewhat of a surprise partner for the program. Maybe there might be some money to be made in this area after all. The initial payment of 12,5 mUSD Kosan will receive should be enough to cover running expenses for 4-5 months, judged by the most recent cash-burns. Not enough in itself to generate much excitement. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next